CD4 and Parkinson disease: In this regard, it is expected that a therapy involving the inhibition of DRD3 confined only to those CD4+ T-cells specific for relevant antigens associated to PD (i.e., nitrated α-synuclein) would exert a stronger therapeutic potential than those therapeutic approaches tested here involving the inhibition of DRD3-signalling in CD4+ T-cells irrespective of their antigen-specificity.